Jason Coloma V Sells $594K of Maze Therapeutics Inc (MAZE) — SEC Form 4, Sep 04, 2026
Open-Market Net Sale · SEC Form 4
−$593,955
Equity position changed by -7.8%
Equity Position
269K sh
291,506 → 268,868
Equity Change
-7.8%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Jason Coloma V CIK 0001676170 |
Director
CEO
|
Jason Coloma V at Maze Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$6,186,761
More from this insider at Maze Therapeutics Inc
| 2026-10-02 | Sell | -$932,260 | View |
| 2026-09-03 | Sell | -$906,999 | View |
| 2026-08-05 | Sell | -$922,315 | View |
| 2026-07-02 | Sell | -$1,034,253 | View |
| 2026-06-24 | Sell | -$725,495 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2 | 2026-09-02 | S - Sale | 9,852 D | $26.38 | -$259,856 | 40,148 | Direct |
| Common StockF1F3 | 2026-09-02 | S - Sale | 1,375 D | $27.12 | -$37,292 | 38,773 | Direct |
| Common StockF1F4 | 2026-09-03 | S - Sale | 11,282 D | $26.01 | -$293,482 | 27,491 | Direct |
| Common StockF1 | 2026-09-03 | S - Sale | 129 D | $25.77 | -$3,325 | 27,362 | Direct |
Footnotes (6)
- F1
- The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units. Show more
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. Show more
- F3
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive. Show more
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive. Show more
- F5
- These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees. Show more
- F6
- These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees. Show more
Related filings at Maze Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
161
institutional managers reporting a position
Largest by reported value
- Frazier Life Sciences Management, L.P. $150M
- Trv Gp Iv, Llc $134M
- Arch Venture Management, Llc $123M
5%+ Holders · 13D/G
6 filers
Other insiders at Maze Therapeutics Inc
-
Atul Dandekar -$241K
-
Harold Bernstein -$435K
-
Atul Dandekar -$203K
-
Harold Bernstein -$255K
-
Phillips Courtney -$105K
GET /v1/forms/4/0001676170-26-000022
API docs
View Original SEC Filing